Laws · Ongoing coverage · 3,206 words

House Speaker and Cannabis Legalization: How Leadership Shapes Federal Policy

This hub explains how the Speaker of the U.S. House of Representatives influences federal cannabis legalization, from controlling the floor schedule and committee referrals to shaping spending riders and negotiating with the Senate and White House. It covers the Speaker's constitutional role, how past leaders handled bills like the MORE Act and the SAFER Banking Act, and what a pro-reform Speaker could change in practice. It also tracks news on Speaker nominations and leadership votes, and clarifies the limits of the office, since legalization still requires Senate passage and a presidential signature.

Last updated November 19, 2026 · 0 updates since publication
The iconic US Capitol dome framed by lush green trees in Washington, D.C.
The Speaker of the House controls which bills reach the floor, so a Speaker who supports cannabis legalization can move reform bills forward in ways an opponent can block. The Speaker cannot legalize cannabis alone: federal change still requires Senate passage, a presidential signature, or executive rescheduling action.

Executive Summary

The House Speaker controls whether federal cannabis reform reaches the floor, which makes the identity and record of the Speaker one of the most consequential variables in marijuana policy. On November 19, 2026, Cannabis Business Times reported that House Democrats nominated a cannabis legalization proponent as their candidate for Speaker, putting the question of leadership attitudes toward marijuana back at the center of the federal reform debate.

The Speaker of the House sets the legislative agenda, appoints members to the Rules Committee, and decides which bills get floor time. Cannabis bills have historically died in committee or never received a vote because leadership declined to schedule them, regardless of rank-and-file support. The House passed the MORE Act twice (in December 2020 and April 2022) only because Democratic leadership chose to prioritize it, and the Senate never took up either version.

This hub explains how the Speakership shapes cannabis policy, traces the history of leadership positions on marijuana, profiles the agencies and advocates who work the issue, and lays out the legal framework: the Controlled Substances Act, the Rohrabacher-Farr (now Joyce-Blumenauer) appropriations rider, the SAFER Banking Act, and the pending rescheduling process at the DEA. It also provides an operator and investor lens on what a pro-legalization nomination does and does not change.

The central finding: a Speaker's personal views matter less than the caucus math, the Rules Committee, and the Senate's 60-vote threshold, but a sympathetic Speaker can still move banking, tax, and appropriations language that directly affects licensed operators. Readers should treat a nomination as a signal, not a statute.

Why This Matters

More than 24 million Americans live in states with adult-use markets, and the federal gatekeeping that constrains those markets runs through the Speaker's office. The legal cannabis industry generates tens of billions of dollars in annual sales and supports hundreds of thousands of jobs, yet it operates in conflict with federal law under 21 U.S.C. § 812, which lists marijuana as a Schedule I substance.

Stakeholders and scale

  • Operators and MSOs: Multi-state operators carry the burden of Section 280E of the Internal Revenue Code, which bars deductions for businesses trafficking in Schedule I or II substances and can push effective tax rates far above those of ordinary businesses.
  • Patients: Medical cannabis patients in 40-plus states face federal prohibition on firearm purchase, federal housing restrictions, and limited research on dosing and interactions.
  • Banks and credit unions: Financial institutions face Bank Secrecy Act exposure when serving plant-touching businesses, which keeps many operators cash-dependent.
  • Veterans and researchers: Scheduling constraints limit clinical research, including on THCA, CBD, myrcene, and limonene pharmacology.
  • Communities harmed by prohibition: Expungement and resentencing provisions in bills like the MORE Act depend on floor access.

The dollar stakes

The tax burden is the sharpest financial lever. Operators routinely cite effective tax rates that dwarf those of non-cannabis peers because of 280E, and the lack of banking access raises insurance, security, and payment-processing costs. Any leadership that schedules banking or tax relief affects the margin structure of the entire industry.

Why the Speaker specifically

Under House rules, the Speaker's party controls the Rules Committee, which governs the terms of debate and amendments. Without Speaker support, a bill can attract hundreds of cosponsors and still never see a vote. That structural reality explains why cannabis advocates track Speaker races as closely as they track presidential primaries.

Background and History

Federal cannabis policy has moved from total prohibition in 1970 to a split system in which a majority of states license marijuana while federal law still treats it as a Schedule I drug. The Speaker's role in that arc has been mostly one of obstruction or neglect, with a brief interval of active sponsorship.

1970: The Controlled Substances Act

Congress enacted the Controlled Substances Act in 1970, placing marijuana in Schedule I, the category for drugs with "no currently accepted medical use" and a high abuse potential. The scheduling was provisional, pending a study by the Shafer Commission, which in 1972 recommended decriminalizing personal possession. Congress and the executive branch ignored the recommendation, and the Schedule I placement stuck for more than five decades.

1996: California opens the state-law door

California voters passed Proposition 215 in 1996, creating the first modern medical marijuana program. Other states followed over the next two decades. The federal government's response, including DEA enforcement actions against dispensaries, set up the federalism conflict that persists today.

2012: Colorado and Washington legalize adult use

Voters in Colorado and Washington approved adult-use legalization in 2012. The Obama Justice Department responded with the 2013 Cole Memorandum, which set enforcement priorities and effectively tolerated state-regulated markets. The Trump administration rescinded that memo in 2018, though broad federal enforcement against licensed operators did not follow.

2014: The appropriations rider

Congress adopted the Rohrabacher-Farr amendment (now typically called Joyce-Blumenauer) in the 2014 spending package, barring the Justice Department from using funds to interfere with state medical marijuana programs. The rider must be renewed in each appropriations cycle, which gives the Speaker and the Appropriations Committee leverage over its continued existence.

2018: The Farm Bill and hemp

The 2018 Farm Bill removed hemp, defined as cannabis with no more than 0.3 percent delta-9 THC by dry weight, from the Controlled Substances Act. That change created the legal pathway for the CBD market and later for contested intoxicating hemp-derived products.

2019 to 2022: Leadership engagement and the MORE Act

The House passed the SAFE Banking Act in September 2019 with a bipartisan vote, and Senate leadership declined to take it up. The House passed the MORE Act, which would remove marijuana from the Controlled Substances Act and fund expungement and reinvestment programs, in December 2020 and again in April 2022. Both passages happened under Democratic House control, showing that majority-party leadership could deliver floor time when it chose to. The Senate never voted on either bill.

2023 to 2024: A Republican House and the rescheduling turn

Republican control of the House beginning in 2023 shifted the agenda. Floor action on legalization stalled, though bipartisan interest in banking persisted, now under the name SAFER Banking Act in the Senate. In October 2022, President Biden directed the Department of Health and Human Services and the Attorney General to review marijuana's scheduling. In August 2023, HHS recommended moving marijuana to Schedule III, and in May 2024 the DEA published a notice of proposed rulemaking (NPRM) to do so. A hearing before an administrative law judge (ALJ) was scheduled and then delayed amid procedural disputes.

2025 and 2026: Rescheduling uncertainty and leadership transitions

The rescheduling process remained unresolved through the Trump administration's return, with advocates and operators watching the DEA, the Department of Justice, and the White House for signals. Meanwhile, congressional leadership contests, including the nomination reported on November 19, 2026, became a proxy for how much floor time cannabis might receive in the next Congress.

How Speaker positions have shifted

Earlier generations of House leaders generally avoided the issue or opposed liberalization. The shift toward leadership-level support mirrored public opinion, which moved from minority support in the 1990s to clear majority support for legalization in national polling over the past decade. Today the question is less whether leaders tolerate the topic and more whether they will spend scarce floor time and political capital on it.

Key Players

Federal cannabis policy is shaped by a small set of agencies, committees, and advocacy organizations whose interests do not always align.

The Speaker and House leadership

The Speaker, the Majority Leader, and the Rules Committee chair collectively decide which cannabis measures advance. A nominee who supports legalization can place banking, expungement, or tax measures on the calendar, attach cannabis provisions to must-pass vehicles, and protect the appropriations rider during budget negotiations. A nominee's personal support does not override caucus divisions: moderate members from competitive districts and members from states with restrictive laws may resist.

Drug Enforcement Administration (DEA)

The DEA administers the Controlled Substances Act's scheduling framework. It published the 2024 NPRM to move marijuana to Schedule III and controls the administrative hearing process. Rescheduling to Schedule III would not legalize adult use, but it would likely free many operators from 280E.

Food and Drug Administration (FDA) and HHS

The FDA and HHS supplied the scientific review underpinning the 2023 recommendation. The FDA also regulates cannabinoid-containing drugs, such as Epidiolex (a CBD-based medicine), and holds jurisdiction over hemp-derived product claims.

Department of Justice

Justice sets prosecution priorities and legal positions in rescheduling litigation. Its stance on enforcement against state-licensed businesses is the practical backstop beneath the appropriations rider.

Treasury and FinCEN

The Financial Crimes Enforcement Network issued guidance in 2014 on how banks can serve marijuana businesses, but the guidance has not eliminated institutional caution. Legislative fixes like the SAFER Banking Act would supply statutory safe harbor.

Congressional champions and opponents

Members from both parties have sponsored cannabis legislation, including bipartisan banking, hemp, and veterans-access bills. Opponents include members who cite public-health, youth-use, and impaired-driving concerns, and some who favor rescheduling but oppose full descheduling.

Industry and advocacy groups

Trade associations representing MSOs and independent operators lobby for banking and tax relief. Drug-policy reform organizations emphasize expungement, equity, and descheduling. Public-health and anti-legalization groups push for stricter potency, marketing, and youth-access controls.

Legal and Regulatory Framework

Cannabis sits at the intersection of the Controlled Substances Act, tax law, banking law, and appropriations riders, and the Speaker's influence touches each one.

The Controlled Substances Act

21 U.S.C. § 812 establishes the five drug schedules. Marijuana's Schedule I status carries criminal penalties under 21 U.S.C. § 841 and blocks federal medical recognition. Congress can remove marijuana from the schedules by statute, as the MORE Act proposed, or the executive branch can reschedule through the administrative process under 21 U.S.C. § 811.

Rescheduling versus descheduling

Rescheduling to Schedule III would acknowledge accepted medical use and lower abuse potential relative to Schedules I and II. It would change the tax treatment under Section 280E, which applies only to Schedule I and II substances. It would not authorize adult-use sales under federal law, and operators would still face FDA and DEA registration questions. Descheduling would remove marijuana from the Controlled Substances Act entirely, an outcome that requires legislation or a very different administrative path.

Section 280E

26 U.S.C. § 280E denies deductions and credits for businesses trafficking in controlled substances listed in Schedules I and II. Cannabis operators can deduct cost of goods sold but not ordinary operating expenses, producing an effective tax burden far above that of comparable businesses.

The appropriations rider

The Joyce-Blumenauer language, carried forward since 2014, bars the Justice Department from spending funds to prevent states from implementing their own medical marijuana laws. Federal courts, including the Ninth Circuit in United States v. McIntosh (2016), have held that the rider limits prosecutions of people who comply with state law. Because it requires annual renewal, appropriations leadership matters every fiscal year.

Banking: SAFE and SAFER

The SAFE Banking Act passed the House in 2019 and was later reintroduced and renamed SAFER Banking in the Senate to add provisions on expungement-related and equity concerns. The measures would shield financial institutions from federal penalties for serving state-legal cannabis businesses. A Speaker who schedules banking votes can force the Senate to respond.

Federalism

The Supreme Court held in Gonzales v. Raich (2005) that Congress may regulate even home-grown marijuana under the Commerce Clause. That decision keeps federal authority intact regardless of state law, and it is why state legalization remains legally fragile without congressional action.

Hemp and intoxicating cannabinoids

The 2018 Farm Bill hemp definition created a gray market in intoxicating hemp-derived products. Congress has debated closing that gap in subsequent farm-bill and appropriations cycles. The Speaker's agenda influences whether those measures move.

State-by-State Breakdown

State policy varies widely, and the congressional delegations from each state shape how leadership counts votes on federal reform. The table below summarizes illustrative states; operators should verify current limits and rules with each state regulator.

StateStatusNotes for federal policy
CaliforniaAdult-use and medicalLargest legal market by population; Proposition 215 (1996) and Proposition 64 (2016); large House delegation with strong pro-reform lean.
New YorkAdult-use and medicalAdult-use law enacted in 2021; regulated market rollout has been gradual; delegation includes leading reform sponsors.
OhioAdult-use and medicalVoters approved adult use in November 2023; legislative adjustments followed; swing-state delegation matters for leadership vote counting.
ColoradoAdult-use and medicalFirst adult-use market (2012); decade of data on tax revenue and public-health outcomes.
MassachusettsAdult-use and medicalAdult use approved in 2016; mature market with municipal control over retail siting.
TexasLimited medical programRestricted compassionate-use program; large Republican delegation that shapes House math.
IdahoProhibitionNo medical or adult-use program; borders legal markets, creating cross-border enforcement questions.

California

In California, the legal market is large but burdened by high taxes, local bans, and a persistent illicit sector. California members have historically led on banking and descheduling bills, and the state's operators are among the most exposed to 280E.

New York

New York legalized adult use in 2021 and has worked through licensing delays and litigation. Its delegation includes some of the House's most visible reform advocates, and the state's market development depends on federal banking clarity.

Ohio

Ohio voters approved adult-use legalization by initiative in November 2023, and the legislature subsequently debated amendments to the voter-approved statute. Ohio illustrates the tension between voter-initiated reform and legislative control, and its House delegation includes members in competitive districts.

Massachusetts and Colorado

Massachusetts and Colorado supply the longest datasets on revenue, youth use, and market maturity. Reform advocates cite their experience; skeptics cite their enforcement and public-health challenges.

Texas and Idaho

Texas and Idaho represent the restrictive end of the spectrum. Their delegations influence whether a Speaker can assemble a majority without relying on narrow margins, and whether Republican leadership alternatives would tolerate banking or hemp measures.

Market and Business Implications

A pro-legalization Speaker nomination changes expectations, but operators should price in the Senate filibuster and the administrative rescheduling track before changing capital plans.

MSO impact

The largest MSOs trade at valuations sensitive to federal-reform headlines. Rescheduling to Schedule III would likely reduce tax liabilities materially by removing 280E exposure, while banking reform would reduce financing costs and widen access to institutional capital. A Speaker willing to schedule votes raises the probability of the second outcome but does not control the first, which runs through the DEA.

Wholesale pricing read

Federal reform affects wholesale pricing indirectly. State markets with oversupply, such as those with low barriers to cultivation licensure, have seen sustained price compression for flower, including popular cultivars like Northern Lights, OG Kush, and Wedding Cake. Federal tax relief would improve operator margins but would not by itself reverse state-level oversupply. Operators should expect state licensing and cultivation caps to remain the dominant price drivers.

Capital flows

Banking reform could open the door to conventional lending, institutional investment, and listing on major exchanges. Investors should distinguish between three scenarios: administrative rescheduling (tax relief, no banking fix), legislative banking reform (financing access, no tax change), and full descheduling (both, plus interstate commerce questions). Each has different winners. Vertically integrated MSOs benefit most from tax relief; smaller independents benefit most from banking access and lower compliance costs.

Interstate commerce

Only full descheduling or a purpose-built statute would permit interstate shipment. A Speaker who supports legalization might advance such language, but state-protected markets and local-ownership preferences make a unified federal framework contentious even among supporters.

Hemp and intoxicating cannabinoids

Operators in the licensed marijuana market have lobbied against unregulated intoxicating hemp products. Leadership decisions on farm-bill and appropriations language will determine whether that gap closes, with direct consequences for dispensary competition.

An operator and investor lens

One practical framework: treat a Speaker nomination as a change in the probability of floor action, not in the probability of enactment. Floor action raises the odds of banking and appropriations protection; enactment still requires 60 Senate votes for most bills. Operators should stress-test models against a no-change case, a Schedule III case, and a banking-only case, and avoid assuming that any single leadership change delivers all three.

What Experts Say

Analysts generally agree that a sympathetic Speaker improves the odds of floor action but disagree on how much it changes the odds of enactment.

Drug-policy reform groups have long argued that leadership attention is the binding constraint on federal progress, pointing to the two House passages of the MORE Act as proof that majority leadership can move the issue. They also acknowledge that Senate rules blocked both bills.

Industry trade associations have emphasized banking and 280E relief as the most achievable near-term goals. Their lobbying positions treat rescheduling as helpful but incomplete, since it leaves adult-use sales federally unlawful and leaves open FDA and DEA registration questions.

Public-health researchers and anti-legalization organizations have urged lawmakers to pair any liberalization with potency limits, marketing restrictions, and impaired-driving standards. Their position is that leadership enthusiasm should not substitute for safeguards.

Legal scholars note that Gonzales v. Raich keeps broad federal authority intact, and that the administrative rescheduling process, with its ALJ hearing and potential litigation, can move on a separate timetable from Congress.

The consistent theme across advocates, operators, and critics is that the Speaker controls the calendar, but the calendar is only the first of several gates.

What's Next

The next decision points are the Speaker vote itself, the structure of the Rules Committee, the FY appropriations cycle, and the status of the DEA rescheduling proceeding.

Calendar and decision points

  • Speaker election: The nomination reported on November 19, 2026 positions the nominee for the floor vote at the start of the new Congress; the outcome depends on caucus margins.
  • Rules Committee composition: Appointments signal whether cannabis measures will receive structured floor consideration.
  • Appropriations: The Joyce-Blumenauer rider must be carried forward in each spending package; watch for attempts to drop or narrow it.
  • DEA rescheduling: Watch for ALJ hearing scheduling, a final rule, or litigation that resets the timeline.
  • Banking: Watch for a standalone SAFER Banking vote or attachment to a larger financial package.

Scenarios

  1. Floor action without enactment: The House passes a banking or reform bill; the Senate stalls. Operators see no immediate change but gain negotiating leverage.
  2. Administrative rescheduling: The DEA finalizes Schedule III. Tax relief arrives for many operators; banking and adult-use questions remain.
  3. Bundled deal: Banking or hemp language rides on a must-pass vehicle. This path historically has the highest enactment odds.
  4. Stalemate: Caucus divisions and Senate rules block action; the status quo holds, and states continue to diverge.

Readers should expect dated update sections on this page as the Speaker election, committee assignments, and DEA proceedings develop.

Further Reading

  • Cannabis Business Times coverage of the nomination: House Democrats Nominate Cannabis Legalization Proponent as Speaker
  • Controlled Substances Act, 21 U.S.C. § 801 et seq.: https://www.law.cornell.edu/uscode/text/21/chapter-13
  • Schedules of controlled substances, 21 U.S.C. § 812: https://www.law.cornell.edu/uscode/text/21/812
  • Section 280E, 26 U.S.C. § 280E: https://www.law.cornell.edu/uscode/text/26/280E
  • DEA Diversion Control Division, scheduling information: https://www.deadiversion.usdoj.gov/schedules/
  • Federal Register, DEA notice of proposed rulemaking on marijuana rescheduling (2024): https://www.federalregister.gov/
  • Congress.gov, MORE Act and SAFER Banking Act bill texts and status: https://www.congress.gov/
  • FinCEN, BSA Expectations Regarding Marijuana-Related Businesses (2014): https://www.fincen.gov/
  • Gonzales v. Raich, 545 U.S. 1 (2005): https://supreme.justia.com/cases/federal/us/545/1/
  • United States v. McIntosh, 833 F.3d 1163 (9th Cir. 2016): https://law.justia.com/cases/federal/appellate-courts/ca9/15-10117/15-10117-2016-08-16.html

Frequently asked questions

What power does the House Speaker have over cannabis legalization?

The Speaker sets the floor schedule, influences which committees receive bills, and works with the Rules Committee to determine which bills and amendments get votes. That gatekeeping role means a Speaker can advance or bury cannabis measures such as the MORE Act or banking reform. The Speaker also negotiates spending bills, where cannabis-related riders often appear.

Can the Speaker legalize marijuana on their own?

No. Federal legalization requires a bill to pass both the House and Senate and be signed by the President. The Speaker can prioritize and schedule legislation in the House, but cannot bypass the Senate, where most cannabis bills have stalled. Rescheduling under the Controlled Substances Act is a separate administrative process run through the DEA and HHS.

Has the House ever passed a cannabis legalization bill?

Yes. The House passed the MORE Act, which would remove cannabis from the Controlled Substances Act, in December 2020 and again in April 2022. Both times it did not advance in the Senate. The House has also repeatedly passed the SAFER Banking Act to protect banks serving state-legal cannabis businesses, which likewise stalled in the Senate.

What is the MORE Act?

The Marijuana Opportunity Reinvestment and Expungement (MORE) Act would deschedule cannabis from the Controlled Substances Act, expunge certain federal marijuana convictions, and create a tax and reinvestment program for communities harmed by prohibition. It was championed in the House and passed the chamber in 2020 and 2022 but was never taken up for a Senate vote.

What are appropriations riders and why do they matter for cannabis?

Riders are provisions attached to spending bills. The Rohrabacher-Farr (now Joyce-Blumenauer) amendment, renewed in annual appropriations, bars the Justice Department from using funds to interfere with state medical cannabis programs. Because the Speaker helps shape how spending bills reach the floor, leadership attitudes can affect whether such protections are preserved or expanded.

How does the Speaker interact with the Rules Committee on cannabis bills?

The Rules Committee decides the terms of debate and which amendments may be offered, and the Speaker effectively controls its majority membership. Cannabis amendments, such as those on banking, veterans' access, or hemp, may be made in order or blocked there, giving leadership significant influence over what the full House can vote on.

How is the Speaker chosen?

The majority party conference nominates a candidate, and the full House elects the Speaker by a majority of members voting at the start of each Congress. The Constitution does not require the Speaker to be a sitting member of the House, though every Speaker has been. Nomination by the majority conference usually decides the outcome.

Does a pro-legalization Speaker guarantee federal reform?

No. A supportive Speaker improves the odds of House floor action, but the Senate's 60-vote filibuster threshold, committee dynamics, and presidential positions remain major obstacles. Past House passage of cannabis bills under supportive leadership did not produce federal law, illustrating the limits of House leadership alone.

What is the difference between rescheduling and legalization?

Rescheduling moves cannabis to a lower schedule under the Controlled Substances Act through a DEA and HHS process, which would ease some restrictions but keep federal controls in place. Legalization or descheduling removes it from the Act entirely and typically requires an act of Congress. The Speaker's influence applies mainly to the legislative route.

Which cannabis bills besides the MORE Act could a Speaker prioritize?

Leadership can prioritize the SAFER Banking Act for financial access, the STATES Act to defer to state cannabis laws, veterans' medical cannabis access measures, and hemp-related provisions in the farm bill. Each can reach the floor through standalone votes, suspension of the rules, or inclusion in larger must-pass legislation.

house-speakerfederal-legalizationcongressmore-actcannabis-policysafer-banking
The CannIntel Daily

The cannabis newsletter you forward to your team.

Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.

No spam. Unsubscribe with one click. 21+ only.